top of page

Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines

Nov 26, 2024

1 min read

Founder and CEO Seulki Lee describes his training in science, part of which was working on GLP-1s years ago, and the founding of the company. He walks us through D&D's pipeline, including oral GLP medicines that have been licensed to Metsera in the United States for development.

https://vimeo.com/1033717662?share=copy

Recent Posts

See All

STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months

STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial human data on its oral PTH1R agonist for hypoparathyroidism in Q1

STIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more